Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older

Phase 3CompletedNCT04648241

Pfizer165 enrolled

Overview

The main purpose of this study is to provide safety and immunogenicity data in Japanese participants.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

165

Conditions

Tick-Borne Encephalitis

Interventions

TBE vaccine 0.5 mLBIOLOGICAL

TBE vaccine 0.5 mL (intramuscular injection).

TBE vaccine 0.25 mLBIOLOGICAL

TBE vaccine 0.25 mL (intramuscular injection).

Eligibility

Sex: ALLMin age: 1 YearHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Japanese male or female participants ≥1 years old at Visit 1. * Participants and/or a legally acceptable representative/parent/legal guardian are willing and able to comply with all scheduled visits, vaccination plan, and other study procedures including completion of the e-diary for 7 days for participants after each of 3 vaccinations. * Participants and/or a legally acceptable representative/parent/legal guardian must be able to be contacted by telephone during study participation. * Participants and/or a legally acceptable representative/parent/legal guardian are capable of giving signed informed consent. Exclusion Criteria: * Major known congenital malformation or serious chronic disorder. * Known history of TBEV infection. * Known history of other flavivirus infection (eg, dengue fever, yellow fever, JEV, West Nile virus). * Known history of infection with HIV, HCV, or HBV. * Immunocompromised participants with known or suspected immunodeficiency. * History of autoimmune disease or an active autoimmune disease requiring therapeutic intervention. * Previous vaccination with any licensed or investigational TBE vaccine, or planned receipt of other flavivirus vaccines apart from JEV vaccine (eg, yellow fever, dengue fever) during the study. Administration of JEV vaccine is prohibited during participation.

Locations (6)

Medical Co. LTA PS Clinic

Fukuoka, Fukuoka, Japan

Azuma kodomo katei clinic

Ebetsu Shi, Hokkaido, Japan

Watanabe Pediatric Allergy Clinic

Sapporo, Hokkaido, Japan

Ohigesenseino Kodomo Clinic

Sapporo, Hokkaido, Japan

Outcomes

Primary Outcomes

Percentage of Seropositive Participants at 4 Weeks After Dose 3

Seropositivity rate based on the immune response was determined by neutralization test (NT). Participants who achieved tick-borne encephalitis virus (TBEV) NT titers \>=1: 10 were considered as seropositive. Exact 2-sided 95% confidence interval (CI) based on the Clopper and Pearson method was presented.

Time frame: 4 weeks after Dose 3

Percentage of Participants With Local Reactions (LR) Within 7 Days After Dose 1

LR:participant or legally acceptable representative/parent/legal guardian using an electronic diary (e-diary). LR included redness, swelling and pain at injection site. Redness and swelling were measured using measuring device units. 1 measuring device unit =0.5 centimeter(cm). Redness and swelling were graded as: for participants \>=12 years of age, mild(greater than\[\>\] 2.0 to 5.0 cm), moderate(\>5.0 to 10.0 cm) and severe (\>10.0 cm); for participants less than (\<)12 years of age, mild(\>0 to 2.0 cm), moderate(\>2.0 to7.0 cm) and severe(\>7.0 cm). Pain at the injection site was graded as: for participants \>2 years of age, mild(does not interfere with activity), moderate(interferes with activity) and severe(prevents daily activity); for participants less than or equal to (\<=)2 years of age, mild(hurts if gently touched) moderate(hurts if gently touched with crying) and severe(causes limitation of limb movement). Exact 2-sided 95% CI based on the Clopper and Pearson method was presented.

Time frame: Within 7 days after Dose 1

Percentage of Participants With Local Reactions Within 7 Days After Dose 2

Local reactions were collected by participant or legally acceptable representative/parent/legal guardian using an e-diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured using measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as: for participants \>=12 years of age, mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm); for participants \<12 years of age, mild (\>0 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at the injection site was graded as: for participants \>2 years of age, mild (does not interfere with activity), moderate (interferes with activity) and severe (prevents daily activity); for participants \<=2 years of age, mild (hurts if gently touched) moderate (hurts if gently touched with crying) and severe (causes limitation of limb movement). Exact 2-sided 95% CI based on the Clopper and Pearson method was presented.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

SUZURAN Children's Clinic

Sapporo, Hokkaido, Japan

Childrens clinic of Kose

Kofu, Yamanashi, Japan

Time frame: Within 7 days after Dose 2

Percentage of Participants With Local Reactions Within 7 Days After Dose 3

Time frame: Within 7 days after Dose 3

Percentage of Participants With Systemic Events (SE) Within 7 Days After Dose 1

SE:participants or legally acceptable representative/parent/legal guardian using e-diary \& included fever:temperature \>=37.5 degree Celsius(C)\&categorized as 37.5to38.4, 38.5 to 38.9,39.0 to 40.0,\>40.0 degree C.Fatigue, headache, muscle pain, joint pain: mild(didn't interfere with activity), moderate(some interference with activity), severe(prevented daily activity). Vomiting: mild(1-2 times in 24 hours\[hrs\]), moderate(\>2 times in 24hrs), severe(required intravenous hydration). Diarrhea: mild(2-3 loose stools in 24hrs), moderate(4-5 loose stools in 24hrs), severe(6 or more loose stools in 24hrs). Decreased appetite:mild(decreased interest in eating),moderate(decreased oral intake), severe(refusal to feed).Drowsiness: mild(Increased sleeping bouts),moderate(slightly subdued interfering with daily activity),severe(disabling not interested in usual daily activity).Irritability:mild(easily consolable), moderate(required increased attention),severe(inconsolable, crying can't be comforted).

Time frame: Within 7 days after Dose 1

Percentage of Participants With Systemic Events Within 7 Days After Dose 2

SE:participants or a legally acceptable representative/parent/legal guardian using e-diary and included fever:temperature \>=37.5 degreeC \& categorized as 37.5 to 38.4,38.5 to 38.9,39.0 to 40.0,\>40.0 degreeC.Fatigue, headache, muscle pain, joint pain: mild(didn't interfere with activity),moderate(some interference with activity), severe(prevented daily activity). Vomiting: mild(1-2 times in 24 hours\[hrs\]), moderate(\>2 times in 24hrs),severe(required intravenous hydration).Diarrhea: mild(2-3 loose stools in 24hrs), moderate(4-5 loose stools in 24hrs), severe(6 or more loose stools in 24hrs). Decreased appetite: mild(decreased interest in eating), moderate(decreased oral intake), severe(refusal to feed). Drowsiness: mild(Increased sleeping bouts), moderate(slightly subdued interfering with daily activity), severe(disabling not interested in usual daily activity).Irritability: mild(easily consolable), moderate(required increased attention),severe(inconsolable, crying can't be comforted).

Time frame: Within 7 days after Dose 2

Percentage of Participants With Systemic Events Within 7 Days After Dose 3

Systemic events collected by participant using e-diary and included fever defined as temperature \>=37.5 degree C and categorized as 37.5 to 38.4, 38.5 to 38.9, 39.0 to 40.0, \>40.0 degree C. Fatigue, headache, muscle pain, joint pain: mild(didn't interfere with activity), moderate(some interference with activity), severe(prevented daily activity). Vomiting: mild(1-2 times in 24 hours\[hrs\]), moderate(\>2 times in 24hrs), severe(required intravenous hydration). Diarrhea: mild(2-3 loose stools in 24hrs), moderate(4-5 loose stools in 24hrs), severe(6 or more loose stools in 24hrs). Decreased appetite: mild(decreased interest in eating), moderate(decreased oral intake), severe(refusal to feed). Drowsiness: mild(Increased sleeping bouts), moderate(slightly subdued interfering with daily activity), severe(disabling not interested in usual daily activity). Irritability: mild(easily consolable), moderate(required increased attention), severe(inconsolable, crying can't be comforted).

Time frame: Within 7 days after Dose 3

Percentage of Participants With Adverse Events (AEs) Within 1 Month After Dose 1

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention. Exact 2-sided 95% CI based on the Clopper and Pearson method was presented.

Time frame: Within 1 month after Dose 1

Percentage of Participants With Adverse Events (AEs) Within 1 Month After Dose 2

Time frame: Within 1 month after Dose 2

Percentage of Participants With Adverse Events (AEs) Within 1 Month After Dose 3

Time frame: Within 1 month after Dose 3

Percentage of Participants With Adverse Events (AEs) Within 1 Month After Any Dose

Time frame: Within 1 month after any Dose

Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study

An SAE was defined as any untoward medical occurrence that, at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect or that is considered to be an important medical event. Percentage of participants with SAEs and the exact 2-sided 95% CI based on the Clopper and Pearson method was presented.

Time frame: From Day 1 up to end of study (up to approximately 13 months)

Secondary Outcomes

Percentage of Seropositive Participants at 4 Weeks After Dose 2

Seropositivity rate based on the immune response was determined by NT. Participants who achieved TBEV NT titers \>=1: 10 were considered as seropositive. Exact 2-sided 95% CI based on the Clopper and Pearson method was presented.

Time frame: 4 weeks after Dose 2

Geometric Mean Titers (GMTs) of TBEV Neutralizing Antibody Titers at 4 Weeks After Dose 2 and Dose 3

GMTs and associated 2-sided 95% CIs were calculated as the mean of the assay results on the natural logarithmic scale based on Student's t distribution and then exponentiating the results. The lower limit of quantitation (LLOQ) value for NT was 5. Assay results below the LLOQ were set to 0.5 × LLOQ.

Time frame: 4 weeks after Dose 2 and Dose 3

Geometric Mean Fold Rise (GMFR) of TBEV Neutralizing Antibody Titers at 4 Weeks After Dose 2 as Compared to Baseline

GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). The LLOQ value for NT was 5. Assay results below the LLOQ were set to 0.5 × LLOQ.

Time frame: From Baseline to 4 weeks after Dose 2

Geometric Mean Fold Rise (GMFR) of TBEV Neutralizing Antibody Titers at 4 Weeks After Dose 3 as Compared to Baseline

Time frame: From Baseline to 4 weeks after Dose 3

Geometric Mean Fold Rise (GMFR) of TBEV Neutralizing Antibody Titers at 4 Weeks After Dose 3 as Compared to 4 Weeks After Dose 2

Time frame: From 4 weeks after Dose 2 to 4 weeks after Dose 3

Percentage of Participants With Neutralizing Antibody Titers >= Lower Limit of Quantification (LLOQ)

The LLOQ value for NT was 5. Assay results below the LLOQ were set to 0.5 × LLOQ. Percentage of participants with NT\>=LLOQ and exact 2-sided 95% CI based on the Clopper and Pearson method was presented.

Time frame: Before Dose 1, 4 weeks after Dose 2, Before Dose 3 and 4 weeks after Dose 3